Gregory Renza
Stock Analyst at RBC Capital
(3.03)
# 1,355
Out of 4,960 analysts
206
Total ratings
38.42%
Success rate
1.59%
Average return
Main Sectors:
Stocks Rated by Gregory Renza
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CDTX Cidara Therapeutics | Maintains: Outperform | $31 → $35 | $66.37 | -47.27% | 3 | May 23, 2025 | |
| ACAD ACADIA Pharmaceuticals | Reiterates: Outperform | $26 | $25.74 | +1.01% | 16 | May 19, 2025 | |
| ADCT ADC Therapeutics | Reiterates: Outperform | $8 | $3.18 | +151.57% | 12 | May 15, 2025 | |
| INO Inovio Pharmaceuticals | Reiterates: Sector Perform | $5 | $1.96 | +155.10% | 11 | May 14, 2025 | |
| EXEL Exelixis | Reiterates: Outperform | $40 | $38.63 | +3.55% | 10 | May 14, 2025 | |
| ONC BeOne Medicines | Maintains: Outperform | $312 → $311 | $313.67 | -0.85% | 2 | May 8, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Outperform | $182 → $172 | $123.11 | +39.71% | 14 | May 7, 2025 | |
| BCYC Bicycle Therapeutics | Maintains: Outperform | $35 → $32 | $7.10 | +350.70% | 3 | May 2, 2025 | |
| AMGN Amgen | Maintains: Outperform | $324 → $320 | $293.72 | +8.95% | 17 | May 2, 2025 | |
| CGON CG Oncology | Maintains: Outperform | $66 → $68 | $26.92 | +152.65% | 3 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $15 | $3.68 | +307.61% | 6 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $13.69 | -12.34% | 6 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $14 | $9.08 | +54.19% | 10 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $26 → $27 | $10.14 | +166.27% | 11 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $61 | $25.12 | +142.83% | 12 | Jan 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $18 | $25.84 | -30.34% | 11 | Jan 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $48 | $2.93 | +1,538.23% | 4 | Jan 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $6 → $10 | $2.90 | +244.83% | 6 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $7 → $10 | $4.11 | +143.31% | 1 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $44 → $47 | $19.23 | +144.47% | 11 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $55 → $57 | $38.80 | +46.91% | 6 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $4 | $6.88 | -41.86% | 3 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $110 → $20 | $5.47 | +265.97% | 7 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $34 | $8.41 | +304.28% | 8 | Sep 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $16 | $5.35 | +199.07% | 1 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $2,160 → $180 | $9.88 | +1,721.86% | 4 | Jun 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $100 → $80 | $1.65 | +4,763.22% | 5 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $105 → $30 | $0.74 | +3,932.26% | 3 | Jun 2, 2020 |
Cidara Therapeutics
May 23, 2025
Maintains: Outperform
Price Target: $31 → $35
Current: $66.37
Upside: -47.27%
ACADIA Pharmaceuticals
May 19, 2025
Reiterates: Outperform
Price Target: $26
Current: $25.74
Upside: +1.01%
ADC Therapeutics
May 15, 2025
Reiterates: Outperform
Price Target: $8
Current: $3.18
Upside: +151.57%
Inovio Pharmaceuticals
May 14, 2025
Reiterates: Sector Perform
Price Target: $5
Current: $1.96
Upside: +155.10%
Exelixis
May 14, 2025
Reiterates: Outperform
Price Target: $40
Current: $38.63
Upside: +3.55%
BeOne Medicines
May 8, 2025
Maintains: Outperform
Price Target: $312 → $311
Current: $313.67
Upside: -0.85%
Jazz Pharmaceuticals
May 7, 2025
Maintains: Outperform
Price Target: $182 → $172
Current: $123.11
Upside: +39.71%
Bicycle Therapeutics
May 2, 2025
Maintains: Outperform
Price Target: $35 → $32
Current: $7.10
Upside: +350.70%
Amgen
May 2, 2025
Maintains: Outperform
Price Target: $324 → $320
Current: $293.72
Upside: +8.95%
CG Oncology
Apr 29, 2025
Maintains: Outperform
Price Target: $66 → $68
Current: $26.92
Upside: +152.65%
Mar 27, 2025
Maintains: Outperform
Price Target: $16 → $15
Current: $3.68
Upside: +307.61%
Mar 26, 2025
Reiterates: Outperform
Price Target: $12
Current: $13.69
Upside: -12.34%
Mar 21, 2025
Maintains: Outperform
Price Target: $16 → $14
Current: $9.08
Upside: +54.19%
Jan 29, 2025
Maintains: Outperform
Price Target: $26 → $27
Current: $10.14
Upside: +166.27%
Jan 15, 2025
Reiterates: Outperform
Price Target: $61
Current: $25.12
Upside: +142.83%
Jan 14, 2025
Reiterates: Sector Perform
Price Target: $18
Current: $25.84
Upside: -30.34%
Jan 9, 2025
Maintains: Outperform
Price Target: $68 → $48
Current: $2.93
Upside: +1,538.23%
Jan 7, 2025
Reiterates: Outperform
Price Target: $6 → $10
Current: $2.90
Upside: +244.83%
Dec 19, 2024
Upgrades: Outperform
Price Target: $7 → $10
Current: $4.11
Upside: +143.31%
Dec 17, 2024
Maintains: Outperform
Price Target: $44 → $47
Current: $19.23
Upside: +144.47%
Dec 10, 2024
Maintains: Outperform
Price Target: $55 → $57
Current: $38.80
Upside: +46.91%
Nov 14, 2024
Reiterates: Sector Perform
Price Target: $4
Current: $6.88
Upside: -41.86%
Nov 5, 2024
Downgrades: Sector Perform
Price Target: $110 → $20
Current: $5.47
Upside: +265.97%
Sep 26, 2024
Maintains: Outperform
Price Target: $31 → $34
Current: $8.41
Upside: +304.28%
Aug 14, 2024
Reiterates: Outperform
Price Target: $16
Current: $5.35
Upside: +199.07%
Jun 27, 2023
Downgrades: Sector Perform
Price Target: $2,160 → $180
Current: $9.88
Upside: +1,721.86%
Mar 16, 2022
Maintains: Sector Perform
Price Target: $100 → $80
Current: $1.65
Upside: +4,763.22%
Jun 2, 2020
Downgrades: Sector Perform
Price Target: $105 → $30
Current: $0.74
Upside: +3,932.26%